fasinumab
mAbexperimental
Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain. — Wikipedia
Clinical trial activity
18 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
13
Phase 3
8
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00856310)
Timeline
Indications
Mechanism of action
- Beta-nerve growth factorINHIBITOR
NGF inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFasinumab ↗
- ChEMBLCHEMBL2109528 ↗
- WikipediaR475 road (Ireland) ↗
Also known as
- fasinumab
- fasinumab
- fasinumab
- r475
- r475
- regn475
- regn-475
- sar-164877
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03949673 | Phase 2 | Apr 8, 2019 | Regeneron, Teva |
| NCT03491904 | Phase 3 | Dec 10, 2018 | Regeneron |
| NCT03691974 | Phase 2 | Oct 8, 2018 | Regeneron, Teva |
| NCT03285646 | Phase 3 | Dec 20, 2017 | Regeneron |
| NCT03304379 | Phase 3 | Oct 26, 2017 | Regeneron |
| NCT03245008 | Phase 2/Phase 3 (Phase 3) | Sep 8, 2017 | Mitsubishi Tanabe |
| NCT03161093 | Phase 3 | Jul 1, 2017 | Regeneron |
| NCT02683239 | Phase 3 | Mar 1, 2016 | Regeneron |
| NCT02620020 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2016 | Regeneron |
| NCT02516618 | Phase 1 | Jul 1, 2015 | Regeneron |
| NCT02447276 | Phase 2/Phase 3 (Phase 3) | May 1, 2015 | Regeneron |
| NCT01239017 | Phase 2 | Nov 9, 2010 | Regeneron, Sanofi |
| NCT01053702 | Phase 2 | Jan 19, 2010 | Regeneron, Sanofi |
| NCT01001923 | Phase 2 | Dec 1, 2009 | Regeneron, Sanofi |
| NCT00991172 | Phase 2 | Nov 1, 2009 | Regeneron, Sanofi |
| NCT01001715 | Phase 2 | Nov 1, 2009 | Regeneron, Sanofi |
| NCT00944892 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2009 | Regeneron, Sanofi |
| NCT00856310 | Phase 1 | Feb 1, 2009 | Regeneron, Sanofi |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 17 | 17 | 3 | 2009 |
| Sanofi | For profit | 7 | 0 | 2 | 2009 |
| Teva | For profit | 2 | 0 | 1 | 2018 |
| Mitsubishi Tanabe | For profit | 1 | 1 | 1 | 2017 |
4 organizations
Page 1 / 1